Plus Therapeutics Introduces Innovative REYOBIQ™
REYOBIQ™ (rhenium Re186 obisbemeda) is currently under clinical evaluation as a treatment for both Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM). This significant announcement comes from Plus Therapeutics, Inc., a clinical-stage pharmaceutical enterprise focused on pioneering advanced therapies for some of the most challenging cancers affecting the central nervous system (CNS).
Regulatory Milestone Achieved
In a recent development, the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ for Plus Therapeutics’ leading drug candidate. This approval marks a vital step in the commercialization process, as the Company prepares to submit its New Drug Application (NDA). Following the NDA submission, all discussions regarding the generic name, rhenium Re186 obisbemeda, will shift to the proprietary name, REYOBIQ™.
Russ Havranek, VP of Corporate Strategy and New Product Planning at Plus Therapeutics, expressed the importance of branding in the commercialization phase: "Developing the REYOBIQ™ brand is crucial for fostering connections among investors, researchers, and patients. It transcends merely denoting the chemical structure, making it relatable and memorable. We aim to enhance both awareness and engagement through this innovative branding.
Highlighting the Therapeutic Potential of REYOBIQ™
REYOBIQ™ stands as a groundbreaking injectable radiotherapy specifically crafted to deliver targeted high dose radiation directly to CNS tumors. This innovative approach seeks to optimize patient outcomes by minimizing off-target effects. By employing rhenium-186, REYOBIQ™ combines the dual benefits of high-energy radiation effective in destroying cancer cells while allowing for real-time imaging through gamma energy. This positions it favorably compared to existing treatments.
The ongoing clinical trials, known as ReSPECT-GBM and ReSPECT-LM, aim to thoroughly investigate the effectiveness of REYOBIQ™. Notably, the ReSPECT-GBM trial receives support from the National Cancer Institute (NCI), part of the NIH, while the ReSPECT-LM trial boasts funding from a substantial $17.6 million grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
About Plus Therapeutics and Its Vision
Based in Houston, Texas, Plus Therapeutics, Inc. endeavors to enhance treatment options for challenging CNS cancers. The Company is engaged in the advancement of targeted radiotherapeutics, aiming to improve clinical outcomes through a combination of precision medicine and innovative delivery mechanisms.
Amidst a network of strategic partnerships, Plus Therapeutics continues to build an efficient supply chain poised for potential future commercialization. Such collaborations will pave the way for the manufacturing and distribution of their promising therapies, including the acclaimed REYOBIQ™.
Contact for Investors
If you have inquiries related to investor relations, please reach out to Jules Abraham, Managing Director of Communications at CORE IR, via email at julesa@coreir.com.
Frequently Asked Questions
What is REYOBIQ™?
REYOBIQ™ is an injectable radiotherapy developed by Plus Therapeutics, aimed at treating CNS tumors like Leptomeningeal Metastases and Recurrent Glioblastoma.
How has the FDA responded to REYOBIQ™?
The FDA has conditionally accepted the proprietary name, REYOBIQ™, as part of the drug's regulatory progress towards commercialization.
Why is branding important for REYOBIQ™?
Branding helps foster connections and understanding among investors, researchers, and patients, creating a recognizable identity beyond the drug's chemical formulation.
What are the main clinical trials for REYOBIQ™?
The primary clinical trials are ReSPECT-GBM and ReSPECT-LM, investigating the drug's efficacy in treating specific CNS cancers.
Who should be contacted for investor-related questions?
Questions from investors can be directed to Jules Abraham at CORE IR via email at julesa@coreir.com.
